Compare GSK plc (GSK) vs Invesco S&P 500 High Div Low Volatility ETF (SPHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Invesco S&P 500 High Div Low Volatility ETF — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Invesco S&P 500 High Div Low Volatility ETF trades at $48.82 (market cap $3.14B). The key difference: GSK plc is far larger — about 29.3× Invesco S&P 500 High Div Low Volatility ETF's market cap, and GSK plc pays a 3.9% dividend while Invesco S&P 500 High Div Low Volatility ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Invesco S&P 500 High Div Low Volatility ETF for 125 Days on average.
| GSK | SPHD | |
|---|---|---|
Market Cap | $91.88B | $3.14B |
Volume | 7,730,529 | 1,461,349 |
Sector | Health | — |
52-Week High | $61.18 | $53.55 |
52-Week Low | $43.24 | $46.96 |
Typical Hold Time | 93 Days | 125 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
SPHD trades at $48.82, up 1.31% today, but technical indicators show a bearish trend with 17 sell signals versus 4 buy signals. The ETF's moving averages are unanimously bearish while oscillators remain neutral. Recent dividend payments of $0.20 and $0.21 demonstrate its income focus, though financial ratios are unavailable in the current data.
The outlook remains cautious given the bearish technical picture and mixed sentiment. While SPHD offers monthly dividend convenience for income investors, concerns about total return performance versus peers like SCHD present risks. Market volatility and yield sustainability are key considerations for potential investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Invesco S&P 500 High Div Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.
Read more on SPHD →
